Study of TRX-920 for Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
The study drug TRX-920 Oral Gel contains SN38, an active metabolite of Irinotecan (CPT-11),
which is a widely prescribed anti-cancer drug that has been approved in many countries for
the treatment of colorectal and pancreatic cancer. TRX-920 is the oral gel formulation that
directly contains SN38 instead of Irinotecan. A series of biology and animal studies have
demonstrated that the TRX-920 Oral Gel could inhibit tumor growth with fewer side effects
compared to Irinotecan.